MAGNET (Multi-arm, Adaptive, Group-sequential trial NETwork) is an international platform trial innovated to streamline the evaluation of potential motor neuron disease (MND) treatments. The idea of a platform trial is that multiple treatments can be tested simultaneously, and more people are randomized into treatment arms rather than placebo. MAGNET’s first sub-study evaluates the efficacy of lithium carbonate in MND patients who have a specific mutation in the UNC13A gene. The Human Studies Unit is supporting the launch of the Australian arm of MAGNET through conducting UNC13A mutation screening of potential candidates. Screening began in early April 2023, with n=24 individuals screened to date.
Restuadi, R., Steyn, F.J., Kabashi, E. et al. Genome Med 14, 7 (2022). https://doi.org/10.1186/s13073-021-01006-6
Allan leads the Systems Genomics group at IMB and has had a leading role in the analysis of the genomic data generated from the SALSA-SGC collection. He has recently been funded to extend the ‘omits data with the inclusion of neurological protein measures in plasma.
Taking results from animal models, this project will screen blood lipids found to be markers of disease progression. Serum and plasma samples accessed from SALSA-SGC will be used for targeted screening of blood lipids knowing that lipid metabolism plays a crucial role in MND. This research will be conducted at the Florey Institute in Melbourne, Victoria, and results are expected late 2022.
Interested in finding out more about this study? Please contact Sophia Luikinga: email@example.com
Work has been undertaken with Illumina over the last 12 months to develop a SNP bead chip that will expand our capacity to screen for mutations associated with MND. The first batch of chips were received early 2022.
van Rheenen, W., van der Spek, R.A.A., Bakker, M.K. et al. Nat Genet 53, 1636–1648 (2021). https://doi.org/10.1038/s41588-021-00973-1